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Abstract.  The phenotypic effects of selectively 
decreasing the levels of S100B  in cultured glial cells 
were analyzed. Two separate antisense approaches 
were utilized for inhibition of S100/3 production: anal- 
ysis of clonal isolates of rat C6 glioma cells contain- 
ing an S100B  antisense gene under the control of a 
dexamethasone-inducible promoter, and analysis of C6 
cells treated with S100/~ antisense oligodeoxynucleo- 
tides. Both antisense methods resulted in a decrease in 
S100B  levels in the cell, as measured by RIA. The in- 
hibition of S100fl production correlated with three al- 
terations in cellular phenotype: (a) a  flattened cell 
morphology; (b) a more organized microfilament net- 
work; and (c) a decrease in cell growth rate. The 
studies described here provide direct evidence for an 
involvement of S100B  in glial cell structure and func- 
tion, and suggest potential in vivo roles for S100fl in 
regulation of glial cell morphology, cytoskeletal orga- 
nization, and cell proliferation. 
S 
I ooB is a calcium binding protein that is synthesized in 
glial cells of vertebrate brain, and that is highly con- 
served in amino acid sequence among vertebrate spe- 
cies (see Donato,  1986;  Van Eldik and Zimlner,  1988  for 
reviews). S100/~ is also a member of a larger class of small, 
acidic proteins with extensive amino acid sequence similari- 
ties. This family of proteins (some of whose sequences have 
been inferred from cDNA sequences) includes calcium bind- 
ing proteins, proteins that increase in cells after growth fac- 
tor  or  serum  stimulation,  proteins  that  increase  upon 
differentiation or transformation, a protein subunit of a tyro- 
sine kinase substrate, and proteins that are found in diseases 
like cystic fibrosis and rheumatoid arthritis (see Winning- 
ham-Major et al., 1989 for references). The observation that 
expression of many of these proteins is altered during cell 
growth or differentiation suggests that they may be involved 
in regulation of these processes. However, little information 
is available about the in vivo roles of any of these proteins, 
including S100/3. 
The biochemistry, localization, and in vitro activities of 
S100B have been studied extensively over the past 20 years, 
and the immunochemical detection of S100/5 is a standard 
procedure  in  diagnostic  pathology.  Based  mostly on  the 
results of in vitro reconstitution studies, several roles  for 
S100/~ in glial cell function have been suggested. S100B has 
been reported to alter protein phosphorylation, microtubule 
disassembly, and an intracellular enzyme (see Van Eldik and 
Zimmer,  1988  for references), suggesting that S100/3 may 
have multiple regulatory activities in glial cells. In addition 
to intracellular functions, there is evidence that some forms 
of S100B may be secreted and function in an extracellular 
role in nervous tissue. For example, S100fl has been detected 
in brain extracellular fluid (Shashoua et al.,  1984)  and in 
conditioned media from glial ceils (Suzuki et al., 1987; Van 
Eldik and Zimmer,  1987),  and a  disulfide-linked form of 
S100/5 has neurotrophic activity; i.e., it can stimulate neurite 
outgrowth  (Kligman  and  Marshak,  1985;  Kligman  and 
Hsieh, 1987; Van Eldik et al., 1988; Winningham-Major et 
al., 1989) and enhance cell survival (Winningham-Major et 
al.,  1989)  in cultures of CNS neurons. 
S100/3 protein levels  appear to be subject to regulation. 
For example,  S100/3 levels  can be  increased in cell lines 
(Tsunamoto et al., 1988; Van Eldik and Zimmer, 1987; Zim- 
mer and Van Eldik,  1989) and in response to activation of 
the  cAMP  signal  transduction pathway (Labourdette and 
Mandel, 1980; Higashida et al., 1985; Zimmer and Van E1- 
dik, 1989). In addition, the gene for human S100fl has been 
mapped to the distal arm of chromosome 21 in the Down's 
Syndrome region (Allore et al., 1988; Duncan et al., 1989), 
and S100B levels have been reported (Griffin et al., 1989) to 
be increased in reactive glial cells of patients with Down's 
syndrome and Alzheimer's disease. The results from our lab- 
oratory and others clearly raise the possibility that S1001~ 
may play critical in vivo roles that affect both the glial cell 
where it is synthesized, and the neuronal cell, a possible tar- 
get of secreted $100/3. Based on this model of S100/3 action 
on both glial and neuronal cells, abnormalities of S100/3 gene 
expression and protein production/targeting could have pro- 
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mechanistic relationship of altered SIOOB levels to cellular 
abnormalities is not known, and there has not been a direct 
analysis of how perturbation of SIOOB levels in a selective 
and specific manner correlates with changes in cell pheno- 
type.  The  development of a  biological system where the 
S100/3 levels can be altered (either increased or decreased) 
in a selective and reproducible manner might provide a use- 
ful system for examination of the role of SIOOB in glial cell 
structure and function. 
In the studies reported here, we have analyzed the effects 
of a selective decrease in SLOG/3  levels in rat C6 glioma cells. 
C6 cells have been used for many years as a model glial cell 
system (Benda et al.,  1968),  and the localization and levels 
of SIOOB in C6 cells have been extensively studied (see Van 
Eldik and Zimmer, 1988 for references). We have previously 
reported that C6 cells contain predominantly, if not exclu- 
sively, the/5 subtype ofSlO0 (Zimmer and Van Eldik, 1988), 
and that S100~ can be released into the conditioned medium 
(Van Eldik and Zimmer, 1987).  Thus, the C6 cell provides 
an  excellent biological  system amenable to  experimental 
manipulations, and useful for studying how inhibition of 
S10Ofl production affects cellular phenotype. 
We report here studies using two "antisense" approaches 
for inhibiting SIOOB  production in C6 cells: (a) characteriza- 
tion of C6 clones containing an SlOOfl antisense gene con- 
struct under the control of a dexamethasone-inducible pro- 
motel  and  (b)  analysis  of C6  cells  treated  with  SIOOB 
antisense oligonucleotides. Our  initial data analyzing the 
phenotypic consequences of selectively decreasing S100/3 
levels  suggest important roles for SIO0/~ in glial cell mor- 
phology, cytoskeletal organization, and growth regulation. 
Materials and Methods 
Cell Culture 
Rat C6 glioma cells were obtained from American Type Culture Collection 
(Rockville, MD) and grown in cx-MEM (Gibco Laboratories, Grand Island, 
NY) supplemented with 2.5% (vol/vol) FBS (Hyclone  Laboratories; Lo- 
gan, LIT), 40 U/ml penicillin, and 40 ttg/ml streptomycin (Gibco Laborato- 
ries). The cells were grown at 37°C in a humidified atmosphere containing 
7%  CO2. C6 cells that contained the pS100AS plasmid were  grown in 
¢x-MEM with FBS that had been treated with charcoal to deplete steroids. 
Steroids were depleted from the FBS by adding activated charcoal (10 g/500 
ml serum) and heating at 55°C for 30 rain while stirring. The sennn/char- 
coal mixture was then centrifuged at 35,000 g for 45 rain at 40C, and the 
supernatant was sterilized  by filtration through 0.22-txm filters. 
Preparation of  SlOOfl Antisense Vector 
A plasmid (pSI00AS) containing the SI00B antisense gone was constructed 
by using a synthetic S100•  gone (Van Eldik et al., 1988). Briefly, the S100fl 
coding region was isolated from pVUSB-1 (Van Eldik et al., 1988) by treat- 
ment with Eco [] and Hind 111. The 289-bp insert was purified by electro- 
elution, treated with T4 pelymerase to generate blunt ends, and ligated into 
the Eco RV site in the polylinker region of the dexamethasone-inducible, 
pMSVneo eukaryotic expression vector (Chung et al., 1988; obtained from 
Dr.  Claire Fraser, National Institutes of Health). 
Ligation, transformation and selection of recombinant plasmids in Esch- 
erichia coli were done as previously described (Van Eldik et al., 1988) and 
orientation of the S100~ insert was determined by restriction enzyme map- 
ping with Sac I, Xba I, and Nru I. The vector containing the SI00B gone 
in the antisense orientation was termed pS100AS. 
Isolation of C6 Clones Containing pSlOOAS 
C6 cells were cotransfeeted with pSI00AS (10 ttg) and a plasmid (pRShGRa; 
10/~g) containing a glucocorticoid receptor insert (Giguere et al.,  1986). 
Transfections  were done by a calcium phosphate precipitation technique 
(Wigler et al.,  1978) and glycerol  shock (Mellon et al.,  1981). Cells that 
stably integrated pSI00AS  were selected by their ability to grow in 400 
/tg/ml geneticin (G418; Sigma Chemical Co.).  Colonies of ceils were sub- 
cloned using cloning rings and expanded in the selection medium. C6 clones 
that contained the S100B antisense gene construct were designated C6-AS1, 
C6-AS2,  etc. 
To induce expression of the S100/5 antisense gone, cells were treated for 
various times with 1/tM dexamethasone (10 td of 1 mM dexamethasone 
in ethanol added per 10 ml medium). Controls received an equivalent con- 
centration of diluent alone (10 t,l ethanol per 10 ml medium). Experiments 
were designed so that at each time point, cells were harvested at similar cell 
densities (80% contluency). 
Analysis of  Morphological Changes 
Morphological examination of ceils containing the pSI00AS  plasmid was 
made by video-enbanced differential interference contrast microscopy, fol- 
lowing  the methods described by Schnapp (1986).  Cells were placed on 
glass coverslips at a density of I  x  104 cells/nil, and grown for 24 h in the 
presence or absence of 1 ~tM dexamethasone (Sigma Chemical Co.,  St. 
Louis, MO). Coversllps were then placed cell side down onto glass micro- 
scope slides and the edges sealed with a mixture of melted lanofin, vaseline, 
and paraffin (1:1:1). Slides were then inverted and placed on a Zeiss Axiovert 
35 microscope mounted inside a 370C air bath as described by Hitt et al. 
(1990). Interference contrast images were made using a 100× Neofluor ob- 
jective, 2.5 × Optovar lens, and Dnge Model 67 video camera. Photographs 
were taken directly from the video monitor. 
The cytoskeletal  proteins actin, tubulin, and vimentin were localized by 
fluorescence  methods.  For these experiments,  cells were grown on glass 
coverslips  in the presence or absence of 1 I~M dexamethasone for 72 h, 
fixed  in 3.7% formaldehyde  for 30 rain at 22"C,  and permeabilized in 
-200C acetone for 7 rain (Welsh,  1983). Actin distribution was visualized 
using phallacidin (Bodipy-phallicidin;  Molecular Probes,  Inc.,  Eugene, 
OR) as an affinity probe (Barak and Yocum, 1981). Tubulin and vimentin 
distributions  were analyzed by immunofluorescence  as previously described 
(Welsh, 1983) using mouse mAbs TUB 2.1 and VIM-13.2 (Sigma Chemical 
Co.), respectively. 
Analysis of SIOOB Levels in Cell Extracts 
S100B protein levels were determined by []A of cell extracts enriched for 
S100B. Ceils were harvested at 80% confluency by rinsing the plates three 
times with PBS,  scraping the cells into PBS, and centrifuging at 3,000 g 
for 5 rain at 4°C to collect the cell pellet. Cell pellets were re,  suspended 
in homogenization buffer (1 vol buffer/vol pellet) containing 50 mM Tris- 
HC1, 1 mM EGTA,  1 mid/~-mercaptoethanol, pH 7.4; and homogenized 
by sonication (three times for 30 s each) using a microprobe on a dismem- 
brator (model 300; Fisher Scientific, Fair Lawn, NJ) at 30% relative energy 
output.  The homogenate was centrifuged at 16,000 g for 5 min at 4oc, the 
resultant supernatant was placed in a boiling water bath for 7 rain, and 
the heat-treated  supernatant was centrifuged again at 16000 g for 5 rain. 
The pH of the final supernatant was lowered to 4.0 by the addition of I M 
H2SO4, and the mixture incubated for 2 h at 4°C.  Precipitated proteins 
were then collected by centrifugation  at 3,000 g for 5 min at 40C. The pellet 
was rcsuspended in RIA buffer (20 mlVl Tris-HC1,  100 mM NaC1, 1 mM 
EDTA, pH 7.6), and the pH of the solution was raised to 7.5 by addition 
of 0.1 N NaOH. The solution was incubated overnight at 4°C and the pH 
was then readjusted  with NaOH to a final pH of 7.5. S100/~ levels in these 
partially purified samples ware measured by []A as p~viously described 
(Zimmer and Van Eldik,  1988). 
Protein determinations were done by the method of Lowry et al. (1951) 
using BSA as a standard. 
Synthesis and Purification of OUgonucleotides 
Oligodeoxynucleotides  were synthesized on an automated solid-phase  syn- 
thesizer (model 38013; Applied Biosystems, Inc., Foster City, CA) by/$-cya- 
noethyl phosphoramidite chemistry.  Crude,  detritylated oligonucleotides 
were dissolved  in 100/tl sterile water or PBS and further purified using 
Sepbadex G-25 spin columns. Spin columns were constructed with a 1-ml 
tuberculin syringe containing sterile siliconized glass wool and filled to the 
0.8-ml level with preswollen,  sterilized Sephadex  G-25 (Pbarmacia Fine 
Chemicals, Piscataway, NJ). Spin columns were washed with 4 ml of sterile 
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tide was added to the resin bed and eluted by centrifugation of the column 
at 1,500 g for 10 rain at 4°C into a sterile tube. Final oligonucleotide  con- 
centration was then determined by spectropbotometry. 
Treatment of C6 Cells with Oligonucleotides 
All studies for determining the effects of S100~ antisense oligonucleotides 
on C6 cells used early passage  cells (<14 passages  after obtaining  cells from 
American Type Culture Collection). Cells were plated at a density of  0.5 × 
104 cells/ml in 24-well tissue culture plates and grown for 24 h in ~-MEM 
containing 2.5% FBS. The serum-containing  medium was then aspirated 
from the cells, and the cells were washed two times in serum-free ~-MEM. 
Cultures were then incubated in serum-free ~-MEM containing 30 #M oli- 
gonucleotides. After a 2-h incubation, FBS was added to the wells (without 
changing the medium) to a final serum concentration  of 2.5 %. Preliminary 
experiments were carried out essentially as described (Holt et al., 1988) to 
demonstrate that the FBS serum lot (lot 1115864; Hyclone Laboratories) 
had low nuclease activity (data not shown). Cells were incubated in the 
presence of oligonucleotides for various times, and cell counts were deter- 
mined with a hemacytometer  at 24-h intervals. In experiments examining 
the effect of oligonucleotides on S100~ levels, experiments were designed 
so that at each time point, cells were harvested at similar cell densities (80% 
confluency). For the studies reported here, cells received  only a single addi- 
tion of oligonucleotide at the beginning of the time course, and there was 
no medium change during the experiment. 
Results 
Isolation of C6 Cells Containing an SlOOf3 
Antisense Gene 
A  eukaryotic expression vector capable of producing RNA 
that is complementary to the coding sequence of an S100/3 
gene was constructed;  key features of this S100/3  antisense 
vector are diagrammatically summarized in Fig.  1.  As de- 
scribed in Materials and Methods, the S100/3 coding region 
was isolated from pVUSB-1, a vector containing a synthetic 
S100/3 gene (Van Eldik et al.,  1988),  and then inserted into 
the polylinker region of the pMSVneo eukaryotic expression 
vector (Chung et al.,  1988). The pMSVneo vector was cho- 
sen for several reasons. First, it allows the inducible expres- 
sion of eukaryotic genes in mammalian cells.  The presence 
of sequences in the long terminal repeat of the mouse mam- 
mary tumor virus allows regulation of expression by addition 
of glucocorticoids to the culture medium.  This is advanta- 
geous because clones can be selected in the absence of in- 
ducer and the effects of gene induction can be followed in the 
same cells.  Second, pMSVneo contains the neomycin resis- 
tance  gene,  allowing  selection  of stably  transformed  cells 
when grown in medium containing the neomycin analogue, 
Geneticin  (G418).  Third,  pMSVneo  contains  a  polylinker 
region with several unique restriction enzyme sites for easy 
insertion  of foreign  DNA.  Fourth,  pMSVneo  contains  an 
ampicillin resistance gene and pBR322 origin or replication, 
allowing initial cloning in bacterial  cells. 
Orientation of the S10013 gene insert was determined by re- 
striction  enzyme mapping,  and  the  vector containing  the 
gene in the antisense  orientation  was designated  pS100AS 
(Fig.  1). C6 cells were transfected as described in Materials 
and Methods, and stable transformants were selected and ex- 
panded  under  (3418  selection.  A  number  of C6-derived 
clones were found to be resistant to G418, and these clones 
have been termed C6-AS1, C6-AS2, et cetera. As discussed 
below,  we  examined  selected  clones for  steroid-inducible 
changes. 
[EcoRV/HindlII]  [EcoRI/EcoRV] 
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Figure 1. SIO0/~ antisense vector. This diagram, while not to scale, 
shows  the  key  features of  the  eukaryotic  expression  vector 
(pS100AS) containing an S100/3 gene in the antisense  orientation. 
A 279-bp fragment containing the entire coding region of a syn- 
thetic  S100/3 gene was isolated from pVUSB-1 (Van Eldik et al., 
1988) by digestion with Eco RI and Hind HI, blunt-ended, and in- 
serted into the Eco RV site of the polylinker region of pMSVneo 
(Chung et al.,  1988). Cloning in E. coli used the ampicillin  resis- 
tance gene (Am/f) and the pBR322 origin of replication (pBR322- 
ori). After transfection of C6 glioma cells, the neomycin resistance 
gene (Neo  r) expressed  from an SV40 origin and early promoter 
allowed selection of positive clones in G418. The dexamethasone- 
inducible  promoter in the mouse mammary tumor virus-long ter- 
minal repeat (MMTV LTR), and the SV-40 early splice and polyad- 
enylation sequences  are also shown. 
Changes in Cell Morphology and Cytoskeletal 
Organization in C6-AS Clones 
Upon addition of dexamethasone to induce expression of the 
S100/~ antisense gene, we observed dramatic changes in cell 
morphology in several of the clones. An example of a repre- 
sentative clone (C6-AS1) showing the morphological changes 
is depicted in Fig. 2. In the absence of dexamethasone,  the 
cells showed the typical bipolar, stellate shape similar to the 
parental, untransfected C6 cells. However, after dexametha- 
sone  addition,  the  majority  of cells  exhibited  a  flattened, 
"fried egg-like" appearance. Quantitation of the relative areas 
of a  representative  population  of cells  by using  Bioquant 
Elite  Software  (R&M  Biometrics,  Nashville,  TN)  demon- 
strated that there was a threefold increase in area after dexa- 
methasone treatment.  The morphological change does not 
appear to be a nonspecific dexamethasone effect,  since the 
changes were not seen in the untransfected C6 cells treated 
with dexamethasone.  Although the time course of the mor- 
phological changes varied with the particular clone, in gen- 
eral the changes were gradual, with a small proportion of the 
cells in a culture showing the flattened, enlarged morphology 
at 24 h  after dexamethasone addition,  and the majority of 
cells affected by 72 h  after dexamethasone addition. 
Dexamethasone treatment of C6-AS clones also resulted 
in  alterations  in  cytoskeletal  organization,  as  assayed  by 
fluorescence  localization  of  cytoskeletal  proteins.  These 
results  are shown in Fig.  3.  Analysis of microfilaments by 
staining with the actin-selective stain,  phallacidin,  showed 
differences in actin distribution in C6-AS1 cells grown in the 
absence (Fig. 3 A) or presence (Fig. 3 B) of dexamethasone 
for 72 h.  After treatment with dexamethasone,  the C6-AS1 
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sense gene induction on cellular 
morphology. A C6 clone (C6-AS/) 
containing  the  S100/~ antisense 
gene under the control of a dexa- 
methasone-inducible promoter was 
grown  for 24  h  in  the  absence 
(lefO or presence (right) of 1/~M 
dexamethasone. Photographs were 
made from a video screen display 
of cells viewed under  Nomarski 
optics  as described  in Materials 
and Methods.  Bar,  1 /~m. 
cells showed a more organized actin stress fiber staining pat- 
tern with flatter, even arrays of microfilament bundles close 
to the culture substrate. The cells also appeared to show less 
membrane ruffling. In contrast to the results with actin stain- 
ing, analysis of intermediate filaments and microtubules by 
staining with antibodies to vimentin (Fig.  3,  C and D) and 
tubulin (Fig.  3, E  and F),  respectively, showed no obvious 
changes  in  the  dexamethasone-treated cells.  These  initial 
data  indicate  that  induction  of the  SIO0/~ antisense  con- 
struct with dexamethasone results  in  a  flattened cell mor- 
phology and changes in the distribution of the microfilament 
network of the cellular cytoskeleton. 
Decreased Levels of SlOOf3 in the C6-AS Clones 
To determine  if the  morphological effects seen  in  C6-AS 
clones correlated with an inhibition of S100/5 production, we 
measured  S100~  levels in  the  cells by radioimmunoassay. 
Three clones were selected for analysis of S100~ levels be- 
fore and  after induction  of antisense  expression  by dexa- 
methasone:  two clones (C6-AS1  and C6-AS2) that showed 
the altered morphology in response to dexamethasone, and 
one clone (C6-AS3) which showed no obvious morphologi- 
cal change in response to dexamethasone. The parental, un- 
transfected C6  cells were also examined.  As discussed  in 
Materials and Methods, cells were treated with dexametha- 
sone for different lengths of time, and S100/5 levels in par- 
tially purified cell extracts were determined by RIA. Because 
the total levels of S100~ varied with the particular clone ex- 
amined, the data for each clone are expressed as a percent- 
age of the S100/3 levels at the 0-h time point (i.e., in the ab- 
sence of dexamethasone). The results for one of the clones 
(C6-AS2) are shown in Fig.  4. 
As can be seen in Fig. 4 A, the addition of dexamethasone 
to the C6-AS2 cells caused a significant, time-dependent de- 
crease in S100/~ levels below control levels (S100~ levels in 
the absence of dexamethasone). Specifically, the S100/3 lev- 
els were only 40% of control at 48 h after dexamethasone; 
by 96 h of dexamethasone treatment, the S100/~ levels were 
only 16% of control levels. The C6-AS1  cells showed a simi- 
lar pattern of inhibition of S100/3 levels after dexamethasone 
treatment (data not shown). In contrast, the addition ofdexa- 
methasone to the parental,  untransfected  C6  cells did  not 
inhibit the levels of S100/3 (Fig. 4 B).  Finally, a clone (C6- 
AS3) that did not show the altered morphology in the presence 
of dexamethasone also did  not  show  a  dexamethasone-in- 
duced decrease in S100~ levels (data not shown). Altogether, 
these data are consistent with the hypothesis that the mor- 
phological and cytoskeletal changes we observe after dexa- 
methasone treatment are a result of a decrease in S10013 lev- 
els in the cells. 
Effects of SlO0~ Inhibition on Cellular Proliferation 
Induction of the $100/~ antisense gene with dexamethasone 
resulted in a decrease in cellular growth rate. For example, 
in one experiment, the addition of dexamethasone to the C6- 
AS1 clone resulted in fewer than half the number of cells in 
the plate after 3 d compared with cells without dexametha- 
sone. However, we found that dexamethasone also inhibited 
the growth rate of the parental, untransfected C6 cells. Thus, 
we could not distinguish between an effect of dexamethasone 
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of vimentin (C and D), and tubulin (E and F) distributions  were done as described  in Materials  and Methods.  Bar, 50 #m. 
alone on growth vs. an effect of SIO0/~ inhibition on growth. 
To address specifically the effect of decreased SIO0/~ levels 
on cell proliferation, we used another method for SIO0/~ in- 
hibition,  the use of $100/$  antisense oligonucleotides. 
We prepared an S100/3 antisense oligonucleotide  whose 
sequence is the inverse complement of 15 bases of the rat 
S100/3 eDNA sequence (Kuwano et al.,  1984), beginning a! 
the ATG codon that corresponds to the initiator methionine. 
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Figure 4. Inhibition of SIO0/~ production in a C6 clone containing 
the S100/3 antisense gene. The C6-AS2 clone (A) and untransfeeted 
C6 cells (B) were grown in the presence of  dexamethasone for vari- 
ous lengths of time. S100/3 levels in cell extracts were determined 
by RIA, and calculated as nanograms S100/3/micrograms  total pro- 
tein. S100/3  levels are expressed as a percentage of  the control levels 
at the 0-h time point (i.e., in the absence of dexamethasone). Bars 
represent the mean  +  SEM of four determinations (two separate 
experiments analyzing two wells per time point). 
As controls, we synthesized the sense oligonucleotide that is 
equivalent to the coding strand of the eDNA in this region, 
and a mismatch oligonucleotide that is equivalent to the an- 
tisense sequence in which two bases have been changed. A 
search of sequence databases  revealed no matches  (other 
than  to  S100/3) of the  oligonucleotides with  any  known 
nucleotide sequence. The sequences of the oligonucleotides 
used in this study are shown in Fig.  5. 
We then tested the effects of addition of the oligonucleo- 
tides to cultures of untransfected C6 cells. We found that C6 
cells  treated  with  the  S100~  antisense  oligonucleotide 
showed morphological changes similar to the stable transfor- 
mants treated with dexamethasone, i.e., they exhibited a flat- 
tened and more spread appearance, with a 4.4-fold increase 
in cellular area. No such c.hanges in morphology were ob- 
served in C6 cells treated with the sense or mismatch oligo- 
nucleotides. In addition, as shown in Fig. 6, treatment of C6 
cells with the antisense oligonucleotide resulted in a time- 
dependent decrease in cellular growth rate, as assayed by cell 
number, when compared with ceils grown in the presence of 
the sense oligonucleotide or in the absence of oligonucleo- 
tide. A significant decrease in cell number was seen by 48 h 
after the addition of  a single dose (30 #M) of  antisense oligo- 
nucleotide. In other experiments, we have seen inhibition of 
cell growth rate with lower doses of antisense oligonucleo- 
tide. We did not see similar inhibition of proliferation when 
the sense or mismatch oligonucleotides were tested. 
We confirmed by RIA that treatment of C6 cells with the 
antisense oligonucleotide resulted in a decrease in intracellu- 
lar S100/~ levels compared with the S100/3 levels in cells 
treated  with  sense  oligonucleotide or untreated cells.  As 
shown in Fig. 7, in cells treated with antisense oligonucleo- 
tide for 72 h, the S100B levels were "o20% that of the un- 
treated cells or cells treated with sense oligonucleotide. Al- 
together,  these data  suggest that  a  selective inhibition of 
S100/~ production in C6 cells results in a decreased rate of 
cellular proliferation, and implicate S100/3 as a component 
integral to glial cell growth. 
Discussion 
We have demonstrated here that  a  selective inhibition of 
S100/~ production in glial cells is correlated with at least 
three phenotypic changes: (a) a more flattened cellular mor- 
phology; (b) an alteration in cytoskeletal organization at the 
level of the microfilament network; and (c) a decrease in cel- 
lular growth rate. Similar results obtained with two distinct 
antisense methods support the conclusion that S100/~ has im- 
portant roles in regulation of glial cell morphology, cyto- 
skeletal structure, and cell proliferation. 
Antisense approaches are increasingly being used with a 
variety of eukaryotic genes in attempts to understand the 
function of specific gene products by inhibiting the produc- 
tion of  the protein and analyzing the functional consequences 
(see Green et al.,  1986 for review). The S100/~ gene (Van 
Eldik et al.,  1988) used in our studies has a 77 % homology 
with the coding region of rat S100~/cDNA (Kuwano et al., 
1984). Previous studies (Holt et al., 1986) showed that com- 
plete homology is not required for inhibition of gene func- 
tion by antisense constructs, and we confirmed here by RIA 
that the S100/3 levels in the cells were decreased after induc- 
tion of the antisense gene construct with dexamethasone. 
The use of an antisense gene under the control of an induc- 
ible  promoter was  also  advantageous  because  antisense- 
containing clones could be selected before S100/3 inhibition 
occurred, thus avoiding potential problems in cloning due to 
decreases in cell growth rate. 
The use of antisense approaches has allowed us to begin 
to address the in vivo roles of S100~ in glial cells. Our data 
suggest that S100/3 is involved in regulation of cell morphol- 
ogy, cytoskeletal structure, and cell proliferation. The obser- 
vation of a more flattened cellular appearance after inhibi- 
tion of S100~ production in C6 cells is consistent with the 
effects seen on microfilament organization, i.e., the flatter, 
more organized actin stress fiber staining pattern and de- 
creases in membrane ruffling. These alterations in microfila- 
Sense  5'  ATG TCT  (;A(; CT(;  (;A(; 3' 
Antisense  3'  TAC AGA CTC  (;AC CTC 5' 
Mismatch  3'  TAG AGA CTC CAC CTC 5' 
Figure 5. Sequences of S10013 oligonucleotides. The sense oligonu- 
cleotide is equivalent to 15 bases of the rat S10013 eDNA sequence 
(Kuwano et al., 1984), beginning  at the ATG codon corresponding 
to the initiator methionine. The antisense oligonucleotide is the in- 
verse complement of the  sense strand sequence. The mismatch 
oligonucleotide is equivalent to the antisense oligonucleotide se- 
quence in which two bases have been changed. The sequences of 
the antisense and mismatch oligonucleotides are depicted in the 3' 
to 5' orientation for ease of comparison with the sense oligonucleo- 
tide. The rat S100/3 eDNA sequence is available from EMBL/Gen- 
Bank/DDBJ under accession number X01090. 
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Figure 6. Effect of S100/3 an- 
tisense oligonucleotides  on cell 
proliferation. As described in 
Materials  and  Methods,  C6 
cells  were  incubated  in  the 
presence of 30 #M antisense 
oligonucleotide  (AS;  solid 
bars) or sense oligonucleotide 
(S;  open  bars)  for  various 
lengths of time, and cell num- 
bers  were  determined.  Bars 
represent the mean + range of 
duplicate cultures from a rep- 
resentative experiment. 
ment  organization  were  somewhat  unexpected,  however. 
Previous in vitro studies have suggested that S100B can affect 
the  microtubule  network.  For example,  in  reconstitution 
studies,  S100/~ has been reported to stimulate microtubule 
disassembly and to interact in  vitro with tubulin or other 
microtubule-associated proteins (Baudier et al., 1982; Endo 
and Hidaka,  1983; Baudier and Cole, 1988; Donato et al., 
1989; Donato and Giambanco,  1989, and references there- 
in). However, under the conditions used in the in vivo study 
reported here, a decrease in S100B levels in C6 glioma cells 
did not appear to affect the microtubule network. Instead, we 
detected alterations in the microfilament network of the cel- 
lular cytoskeleton. 
Our studies demonstrate the need for a detailed in vitro 
analysis of S100B effects on microfilaments. These kinds of 
studies might provide insight into molecular mechanisms in- 
volved in the effects we observed. For example, these studies 
might elucidate whether S100~ has a direct effect on compo- 
nents of the microfilament structure (such as actin or actin- 
binding proteins) or whether the effects are more indirect 
(such  as  through  protein  phosphorylation/dephosphoryla- 
tion mechanisms). Our results are consistent with a model 
whereby S100B may affect both microfllaments and microtu- 
bules, and that the balance of cytoskeletal structure and dy- 
namics may be related to the levels and/or localization of 
SIOOB. The availability of glial cell lines amenable to ex- 
perimental manipulation and that show selective decreases 
in S100B levels provides a potential starting point for directly 
testing these possibilities. 
In the studies reported here, we also showed that inhibition 
of SIOOB  production in C6 cells is correlated with an inhibi- 
tion of cellular proliferation rate. This result was not unex- 
pected, sinc  e a potential role for S100~/in cellular growth 
processes is suggested by its sequence similarity to a number 
of proteins that appear to be growth related; i.e., their ex- 
pression correlates with cell cycle or cell growth parameters. 
Our results suggest that the levels or concentration of S100/~ 
in the glial cell is related to the rate of cellular proliferation. 
At this time,  it is unclear whether SIOOB is affecting cell 
growth as an essential compound (i.e.,  necessary but not 
sufficient) or as an active, regulatory component used by the 
cell to control its proliferation. Previous evidence has impli- 
cated S100 in stimulation of [3H]thymidine incorporation in 
certain cells (Klein et al.,  1989) or in regulation of progres- 
sion through the cell cycle (Marks et al.,  1990).  However, 
a direct demonstration that increases in S100/3 levels corre- 
late with increased cell growth or that S100B actively stimu- 
lates increases in glial cell number has not yet been reported. 
Studies examining a potential regulatory role for SIOOB in 
C6 cell proliferation are in progress. 
Interestingly, the cellular parameters affected by reduction 
of S100B levels are also affected by the process of cellular 
transformation. The effects of decreased S100B levels on cell 
morphology and growth rate are consistent with a reversal 
of the transformed phenotype of the parental C6 glioma cell 
line. Microfilament stress fibers appear to be indicators of 
the dependence of normal cells on anchorage to a substra- 
tum, and transformation of many cell types by viral infection 
or oncogene activation results in the loss of this flattened 
morphology and the acquisition of the rounded appearance 
common to C6 cells (for review, see Burridge, 1986). Relat- 
edly, the process of transformation can often increase the 
growth rate of a cell population in low concentrations of se- 
rum or growth factors (Holley, 1975). As inhibition of SIOOB 
production in the transformed C6 cells resulted in a pheno- 
type more characteristic of normal cells,  it is  interesting 
to speculate that S100B may play an important role in media- 
tion of some aspects of transformation. In this respect, it will 
be important to  determine the  effects of S100/3 on other 
parameters of transformation such as anchorage-independent 
growth,  foci  formation,  and  activities of certain  growth- 
related kinases. 
The results reported here, taken together with previous 
studies, suggest that homeostasis of S100/~ levels in the glial 
cell may be important for normal glial and neuronal func- 
tion. While the mechanistic relationship of aberrant produc- 
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Time  after  oligonucleotide  addition  (h) 
Figure 7. Inhibition of S100/~ production in C6 cells treated with 
antisense oligonucleotides. C6 cells were treated with 32 #M an- 
tisense oligonucleotide (A) or sense oligonucleotide (B) for various 
lengths of time. S100fl levels in cell extracts were determined by 
RIA,  and calculated as nanograms S100/~/micrograms total pro- 
tein. S100/3  levels are expressed as a percentage of  the control levels 
(the levels in untreated C6 cells at each time point). Bars represent 
the mean +  range of duplicate cultures from a representative ex- 
periment. 
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observations are consistent with the hypothesis that abnor- 
mal  regulation of S10013 levels  may  lead  to  specific neu- 
ropathologies: (a) a form of S100/3 has neurotrophic  activity 
in CNS ~, (b) the human S100/3 gene is localized to the Down 
syndrome region of chromosome 21, raising speculation that 
S100/3 may be involved in neurologic deficits associated with 
Down's syndrome or Alzheimer's disease;  (c) S10013 inter- 
acts in vitro with a microtubule-associated protein that is a 
component  of  neurofibrillary  tangles;  and  (d)  the  data 
presented here suggest an important role for S100fl in cellu- 
lar  structure  and proliferation.  The  studies  reported here 
have provided new perspectives on possible in vivo roles of 
S100/3  in glial cell morphology,  cytoskeletal organization, 
and  growth  regulation.  In  addition,  these  data  provide  a 
framework for future studies aimed at defining the molecular 
mechanisms by which S100fl is involved in nervous system 
development and maintenance. 
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